Leuprolide Dosing & Reconstitution Guide
Dosing Protocol
Route: Intramuscular (Lupron Depot) or Subcutaneous (Eligard) Frequency: Monthly, every 3 months, every 4 months, or every 6 months depending on formulation Dose Range: Prostate cancer: 7.5 mg monthly, 22.5 mg q3mo, 30 mg q4mo, or 45 mg q6mo. Endometriosis: 3.75 mg monthly or 11.25 mg q3mo for 6 months. CPP: 7.5-15 mg monthly (weight-based).
Timeline & Pharmacokinetics
Onset: 2-4 weeks (testosterone suppression) Half-Life: ~3 hours Steady State: 2-4 weeks (depot formulations) Time to Results: 2-4 weeks for hormonal suppression Washout: 4-12 weeks depending on depot formulation
Storage
Lyophilized: Store at 25 °C (77 °F); excursions permitted to 15-30 °C. Lupron Depot kits may be stored at room temperature. Reconstituted: Use immediately after reconstitution; do not store
Injection Sites
Gluteal muscle (IM for Lupron Depot), Abdomen (SC for Eligard), Upper arm
Safety & Contraindications
Safety: Hot flashes/vasomotor symptoms (most common, up to 55-80% of patients) Bone mineral density loss with prolonged use (limit treatment to 6 months for endometriosis without add-back therapy) Initial testosterone/estrogen flare during first 1-2 weeks: may worsen bone pain or urinary symptoms in prostate cancer (can be prevented by concurrent anti-androgen)
Contraindications: Pregnancy (Category X; may cause fetal harm); Undiagnosed abnormal vaginal bleeding; Hypersensitivity to GnRH, GnRH agonists, or any component of the formulation